SCHEMBL15840563

SCHEMBL15840563

CC(=O)c1cccc(NC(=S)Nc2ccc(NS(=O)(=O)c3ccc(C)cc3)cc2)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.64
HTT P42858 3/20 0.64
CYP1A2 P05177 1/20 0.64
CYP3A4 P08684 1/20 0.64
CYP2D6 P10635 1/20 0.64
CYP2C9 P11712 1/20 0.64
CYP2C19 P33261 1/20 0.64
RECQL P46063 1/20 0.64
LMNA P02545 6/20 0.64
MEN1 O00255 5/20 0.64
KMT2A Q03164 5/20 0.64
ALDH1A1 P00352 5/20 0.64
ALOX12 P18054 2/20 0.64
HPGD P15428 2/20 0.64
SMN1; SMN2 Q16637 3/20 0.62
NPSR1 Q6W5P4 2/20 0.62
NPC1 O15118 2/20 0.60
RAB9A P51151 2/20 0.60
GAA P10253 1/20 0.60
TCF4 P15884 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15840727 0.88 FFAR4 (0.63) MAPTHTTCYP1A2CYP3A4CYP2D6
SCHEMBL6959526 0.87 TCF4 (0.75) MAPTHTTCYP1A2CYP3A4CYP2D6
SCHEMBL30926644 0.87 MAPT (0.72) MAPTHTTCYP1A2CYP3A4CYP2D6
SCHEMBL27181232 0.87 MAPT (0.72) MAPTHTTCYP1A2CYP3A4CYP2D6
SCHEMBL13453830 0.81 ALDH1A1 (0.65) MAPTHTTLMNAMEN1KMT2A
SCHEMBL12338982 0.79 MAPT (1.00) MAPTLMNAMEN1KMT2AALDH1A1
SCHEMBL3767094 0.79 MAPT (1.00) MAPTLMNAMEN1KMT2AALDH1A1
SCHEMBL5456725 0.79 ALDH1A1 (0.83) MAPTCYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL16358463 0.79 GPR55 (0.80) MAPTCYP2C9CYP2C19RECQLLMNA
SCHEMBL15840818 0.78 PPIA (0.74) MAPTRECQLLMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140179681-A1 METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT Errico, Joseph P. (US) 2014-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140179681-A1 METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT EGFR, ERBB2, ERBB3 MAPT 1076/4885HTT 1693/4885CYP1A2 3985/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.